NSE ScannerAgri, Sugar & Edible Oils · Agricultural Commodities/Milling · NSE: NATHBIOGEN · data 2026-10-31
Nath Bio-Genes (India) Ltd.
In plain words
Price: 35.8% below its 52-week high of ₹204.
Delivery: 73.2% of traded shares were kept for delivery over the last 10 sessions, against 75.0% over the last 60.
Latest results: a net profit of ₹32 cr for the quarter ended Jun 2026 (-13.5% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹490 cr |
| Net profit (last 12 months) | ₹39 cr |
| Sales growth, 3 years (yearly) | 15.2% |
| Profit growth, 3 years (yearly) | 5.9% |
At a glance
Promoters 45.6% (unchanged in a year), pledged 13.8%, institutions 0.2%.
P/E 6.4, dividend yield 1.5%. Price relative to earnings and book value (low is cheaper, not better).
ROE 6.3%, ROCE 7.3%, operating margin 9.3%: how much profit it earns on the money it uses.
Debt/equity 0.20, Profit growth 5.9% and sales growth 15.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (6.3%).
- Promoters have pledged 13.8% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
NATHBIOGEN Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹328.4 crore, up 15.8% YoY and up 536.6% QoQ.
Net profit was ₹32.26 crore, down 13.5% YoY and a turn to profit from a loss last quarter.
Operating margin was 10.7% (13.5% a year ago).
EPS was ₹16.98, down 13.3% YoY and positive against a negative EPS last quarter.
NATHBIOGEN के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹328.4 करोड़; पिछले साल की तुलना में 15.8% की बढ़त, पिछली तिमाही की तुलना में 536.6% की बढ़त।
शुद्ध मुनाफ़ा: ₹32.26 करोड़; पिछले साल की तुलना में 13.5% की गिरावट, पिछली तिमाही के घाटे से मुनाफ़े में आया।
ऑपरेटिंग मार्जिन: 10.7% (एक साल पहले 13.5%)।
EPS: ₹16.98; पिछले साल की तुलना में 13.3% की गिरावट, पिछली तिमाही के ऋणात्मक EPS से धनात्मक हुआ।
NATHBIOGENના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹328.4 કરોડ; ગયા વર્ષની સરખામણીએ 15.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 536.6% વધારો.
ચોખ્ખો નફો: ₹32.26 કરોડ; ગયા વર્ષની સરખામણીએ 13.5% ઘટાડો, ગયા ક્વાર્ટરની ખોટમાંથી નફામાં આવી.
ઓપરેટિંગ માર્જિન: 10.7% (એક વર્ષ પહેલાં 13.5%).
EPS: ₹16.98; ગયા વર્ષની સરખામણીએ 13.3% ઘટાડો, ગયા ક્વાર્ટરના નકારાત્મક EPSથી હકારાત્મક થઈ.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 70.3% over the last 20 sessions vs 83.6% in the 40 before (0.84x); shares delivered per day 0.26x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 18 Sept 26Results Q1 FY27 results: profit −13.5% YoY +2.5% next session
- 11 Sept 26Dividend Dividend ₹2 (ex-date) -3.7% next session
- 4 May 26Results Q4 FY26 results: net profit ₹0 cr -11.7% next session
- 31 Jan 26Results Q3 FY26 results: profit −39.6% YoY -1.8% next session
- 13 Nov 25Results Q2 FY26 results: profit +147.7% YoY +0.6% next session
- 14 Aug 25Dividend Dividend ₹2 (ex-date) -0.6% next session
- 11 Jul 25Results Q1 FY26 results: profit +11.8% YoY -3.7% next session
- 23 Jan 25Results Q3 FY25 results: profit −30.8% YoY -1.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹328 cr | ₹32 cr | -13.5% | 10.7% | 16.98 |
| Mar 2026 | ₹52 cr | ₹-0 cr | — | 8.7% | -0.79 |
| Dec 2025 | ₹66 cr | ₹2 cr | -39.6% | 5.4% | 0.84 |
| Sept 2025 | ₹44 cr | ₹3 cr | +147.7% | 13.9% | 1.4 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 45.60% | 45.60% | 45.60% | 45.60% |
| Foreign institutions (FII) | 0.19% | 0.27% | 0.23% | 0.31% |
| Domestic institutions (DII) | 0.01% | 0.01% | 0.01% | 0.01% |
| Mutual funds | 0.01% | 0.01% | 0.01% | 0.01% |
| Retail investors | 24.98% | 25.66% | 26.08% | 26.31% |
| Number of shareholders | 32,186 | 32,564 | 33,031 | 33,550 |
Common questions
What was Nath Bio-Genes (India) Ltd.'s latest quarterly profit?
Nath Bio-Genes (India) Ltd. reported a net profit of ₹32 cr for the quarter ended Jun 2026 (-13.5% on the same quarter a year earlier), on revenue of ₹328 cr.
How much do promoters hold in Nath Bio-Genes (India) Ltd.?
Promoters held 45.60% of Nath Bio-Genes (India) Ltd. at the end of Sept 2026, with 13.78% of promoter shares pledged.
Is Nath Bio-Genes (India) Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.2.
What is Nath Bio-Genes (India) Ltd.'s P/E ratio?
About 6.4, based on the last 12 months' earnings and a price of ₹131.01 (data 2026-10-31).
What is the 52-week high and low of Nath Bio-Genes (India) Ltd.?
The 52-week high is ₹204 and the 52-week low is ₹126.15.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Nath Bio-Genes (India) Ltd. | ₹131.01 | ₹250 cr | 6.4 | — | 6.3% | 7.3% | 0.2 | -22.1% |
| KCP Sugar & Industries Corp. Ltd. | ₹24.5 | ₹276 cr | 7.3 | — | 2.4% | -0.4% | 0.28 | -21.8% |
| Axita Cotton Ltd. | ₹7.19 | ₹276 cr | 29.4 | 3.7 | 3% | 5.9% | 0.28 | -6.1% |
| Ponni Sugars (Erode) Ltd. | ₹320 | ₹275 cr | 4.9 | 0.5 | 8.7% | 4.5% | 0 | +4.6% |
| Vijay Solvex Ltd. | ₹719 | ₹230 cr | 9.7 | — | 5.6% | 9% | 0.18 | +1.3% |
| Jay Shree Tea & Industries Ltd. | ₹77.75 | ₹224 cr | — | — | -6.1% | -14.4% | 1.06 | -20.3% |
Compare NATHBIOGEN with KCPSUGIND in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NATHBIOGEN in NSE Scanner →